Authors
Latest:
A Forecasting Rx for Pharmacy Benefit ManagersBuilding an effective drug forecasting model today requires a revamped approach.
Latest:
The Changing Landscape of Digital TrialsRichard Young, Vice President of Strategy, Vault CDMS and Tim Davis, Vice President of Strategy, MyVeeva for Patients, discuss the future of digital trials and their impact in the industry.
Latest:
The Pharma Leadership Challenge: Thawing the “Frozen” Middle ManagersThe challenge for senior leadership is to enable the layers of middle management to work to their full potential. Mike Straw argues that ‘failing fast’ should become the new mantra if pharma is going to drive greater innovation and creativity.
Latest:
Market Access in UkraineOn September 16, 2014, the Ukrainian and European parliaments ratified the EU–Ukraine Association Agreement (AA), providing for harmonization of many spheres of Ukrainian legislation with EU policy.
Latest:
Market Access in UkraineOn September 16, 2014, the Ukrainian and European parliaments ratified the EU–Ukraine Association Agreement (AA), providing for harmonization of many spheres of Ukrainian legislation with EU policy.
Latest:
What AR (Augmented Reality) & Apple Vision Pro Could Mean to Health & Life Sciences Sector Navigating the New RealityEVERSANA's chief innovation discusses his experience with Apple's new device and how he thinks it might impact the life sciences industry.
Latest:
Value-Based Healthcare in the UKJill E. Sackman and Michael Kuchenreuther look at some of the pricing and reimbursement challenges in the UK and offer strategies manufacturers should consider for sustainable success.
Latest:
Europe Sees Pressure to Reduce Environmental Impact of PharmaceuticalsPressure is mounting on European legislators to introduce tighter regulations at both the European Union (EU) and national levels on the potentially harmful impact of pharmaceuticals on the environment.
Latest:
New Social Media Guidelines: What FDA Says, and What It MeansEarlier this year, FDA promised three sets of guidelines to clarify using social media for pharma marketing. Last week it delivered two of them
Latest:
EU Strengthens Transatlantic LinksThe European Union's extensive links with the US FDA and Health Canada have reached a further level of maturity, writes Peter O' Donnell.
Latest:
Bringing Fibroblasts to the Spotlight: Q&A with FibroBiologicsThese therapies may provide more stable treatments than stem cell therapies.
Latest:
The Rise and Rise of Video MarketingIn less than a decade, online video marketing has moved from a standing start to become an essential part of the digital marketing mix
Latest:
Omnicom & Publicis 5 Questions to Frame the DealSince the Omnicom-Publicis merger was announced in late July, it appears the only sources that have not commented on the joining of the superpowers are the President, the Pope, and WikiLeaks.
Latest:
Successful Social Communications The What Vs The HowGo to any communications seminar, forum, convention or workshop right now and the program will be populated with the latest and greatest trends in social communication platforms and how important these are if you want to be successful
Latest:
Assessing the Value of Retrospective Studies Real World Data Real World ApplicationsThe value of retrospective studies cannot be overstated. Retrospective studies affect many healthcare sectors, including the pharmaceutical industry and general public health
Latest:
Orphan Drug Laws A Pharmacists PerspectivePharm Exec’s sister organization CBI hosted its annual Orphan Drug Innovation Summit in Philadelphia on July 17-18. This is a topic that I have professional interest in, as well as a general curiosity.
Latest:
Challenges to the Specialty Business ModelBiopharmaceutical drug discovery companies have progressively tailored their pipelines to specialty therapeutic areas and smaller patient populations.
Latest:
Challenges to the Specialty Business ModelBiopharmaceutical drug discovery companies have progressively tailored their pipelines to specialty therapeutic areas and smaller patient populations.
Latest:
Challenges to the Specialty Business ModelBiopharmaceutical drug discovery companies have progressively tailored their pipelines to specialty therapeutic areas and smaller patient populations.
Latest:
Messaging in Healthcare: Making Sound and Fury Signify SomethingRecently, there was a bit of a dust-up over whether it was appropriate for the Secretary of Health and Human Services (HHS) to engage the National Football League (NFL) to help HHS with the process of drumming-up enrollment for health insurance exchanges. In the end, the NFL and other sports leagues decided they were not going to be involved fearing the appearance of taking political sides.
Latest:
Medicare “Wasting Billions of Dollars”, Says StudyPoorer people are being prescribed more expensive branded drugs. Is that bad? According to a new investigation it is. And it is costing the taxpayers a shovel-load of money. Furthermore, it’s unnecessary.
Latest:
Value-Based Healthcare in the UKJill E. Sackman and Michael Kuchenreuther look at some of the pricing and reimbursement challenges in the UK and offer strategies manufacturers should consider for sustainable success.
